AMBELVIST - (0.5158GM/2ML (257.9MG/ML), 1.93425GM/7.5ML (257.9MG/ML), 2.579GM/10ML (257.9MG/ML), 3.8685GM/15ML (257.9MG/ML), 7.737GM/30ML (257.9MG/ML), 16.7635GM/65ML (257.9MG/ML); SOLUTION)

Generic Name	GADOQUATRANE	**Innovator**	Bayer
Dosage	0.5158GM/2ML (257.9MG/ML), 1.93425GM/7.5ML (257.9MG/ML), 2.579GM/10ML (257.9MG/ML), 3.8685GM/15ML (257.9MG/ML), 7.737GM/30ML (257.9MG/ML), 16.7635GM/65ML (257.9MG/ML); SOLUTION	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	AMBELVIST is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: • the central nervous system (brain, spine, and associated tissues) • the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.